Literature DB >> 17102109

Management and treatment of pheochromocytomas and paragangliomas.

Massimo Mannelli1.   

Abstract

Pheochromocytomas and paragangliomas are rare neural crest-derived tumors of sympathetic (generally catecholamine producing) or parasympathetic (rarely catecholamine producing) origin. Patients affected by these tumors present with a variable clinical picture, often making diagnosis troublesome. Surgery is the treatment of choice, but requires appropriate medical management before, during, and after tumor resection. Appropriate follow-up of patients is particularly important to identify recurrences, remaining disease, or developing malignancy. Currently, however, no firm guidelines exist about what form follow-up should take. There is also a general lack of prospective studies establishing the best approaches for management and treatment of the tumor. Choice of the many available different therapeutic options instead usually depends on institutional experience and clinical setting, which may vary for different groups of patients. At the First International Symposium on Pheochromocytoma (ISP2005), held in Bethesda in October 2005, a panel of experts addressed and discussed the many therapeutic options and problems associated with management and treatment of patients with pheochromocytoma, reporting their personal experience and sharing their opinions with those of patient representatives. The aim of this special Discussion Session was to reconcile differences of opinion and reach agreement about appropriate management and therapeutic options. This article summarizes the discussion and the recommendations derived from that session.

Entities:  

Mesh:

Year:  2006        PMID: 17102109     DOI: 10.1196/annals.1353.044

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

1.  Surgery: Risks of hemodynamic instability in pheochromocytoma.

Authors:  Graeme Eisenhofer; Stefan R Bornstein
Journal:  Nat Rev Endocrinol       Date:  2010-06       Impact factor: 43.330

2.  SAGES guidelines for minimally invasive treatment of adrenal pathology.

Authors:  Dimitrios Stefanidis; Melanie Goldfarb; Kent W Kercher; William W Hope; William Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2013-09-10       Impact factor: 4.584

3.  Case - Bladder paraganglioma in a pediatric patient.

Authors:  Armaan K Malhotra; Ryan Yan; Raymond Tabeshi; Helen Nadel; Henry Tran; John Masterson
Journal:  Can Urol Assoc J       Date:  2018-02-06       Impact factor: 1.862

4.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 5.  Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.

Authors:  Amrish Jain; Rossana Baracco; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2019-01-02       Impact factor: 3.714

Review 6.  Therapeutic goals in patients with pheochromocytoma: a guide to perioperative management.

Authors:  N Azadeh; H Ramakrishna; N L Bhatia; J C Charles; F Mookadam
Journal:  Ir J Med Sci       Date:  2015-12-09       Impact factor: 1.568

Review 7.  Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.

Authors:  Camilo Jimenez; Eric Rohren; Mouhammed Amir Habra; Thereasa Rich; Paola Jimenez; Montserrat Ayala-Ramirez; Eric Baudin
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

Review 8.  A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.

Authors:  Ioannis Ilias; Karel Pacak
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

Review 9.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study.

Authors:  Henrique Vara Luiz; Mary Jane Tanchee; Maria G Pavlatou; Run Yu; Joan Nambuba; Katherine Wolf; Tamara Prodanov; Robert Wesley; Karen Adams; Tito Fojo; Karel Pacak
Journal:  Clin Endocrinol (Oxf)       Date:  2016-04-15       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.